U.S. flag

An official website of the Department of Health & Human Services

AHRQ: Agency for Healthcare Research and Quality

Search AHRQ

For an exact phrase match, enclose search terms in double quotes.

Go to Advanced Search
Go to Basic Search

Results

Total Results: 1,643 records

Showing results for "factor".

  1. Medical Therapies for Locally Advanced Gastric Adenocarcinoma (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/gastric-cancers-protocol-amendment.pdf
    May 02, 2025 - instability-high [MSI-H] or mismatch repair-deficient [MMR-deficient], claudin, human epidermal growth factor … oxaliplatin and docetaxel; FOLFOX = leucovorin, fluorouracil, and oxaliplatin; HER2 = human epidermal growth factor

  2. Effective Health Care (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0262_05-11-2007.pdf
    January 01, 2007 - Effective Health Care Topic Number(s): 0111 Document Completion Date: 5-19-09 1 Results of Topic Selection Process & Next Steps  Urinary incontinence will go forward for refinement as an update to or expansion of an existing comparative effectiveness or effectiveness review. The scope of thi…

  3. Topic 0484 Treatments for Fecal Incontinence NSD FINAL SJ (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND-0572-140408.pdf
    January 09, 2014 - Topic 0484 Treatments for Fecal Incontinence NSD FINAL SJ § Comparative effectiveness of treatments of fecal incontinence in women- Nomination Summary Document …

  4. Contrast-Induced Nephropathy (CIN): Current State of the Evidence on Contrast Media and Prevention of CIN (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/pdf/nephropathy-contrast-induced_clinician.pdf
    August 01, 2016 - The osmolality of a contrast medium is a key factor in determining its nephrotoxicity.

  5. Disposition of Comments: CER 230 Therapies for Clinically Localized Prostate Cancer (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/cer-230-prostate-cancer-comments.pdf
    September 17, 2020 - Disposition of Comments: CER 230 Therapies for Clinically Localized Prostate Cancer Comparative Effectiveness Review Disposition of Comments Report Title: Therapies for Clinically Localized Prostate Cancer Draft report available for public comment from June 01, 2020 to June 29, 2020. Citation: D…

  6. Liver-Cancer Executive (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/liver-cancer_executive.pdf
    October 01, 2014 - Imaging techniques are rapidly evolving, which is another factor that could affect applicability.

  7. S23 (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/s23.pdf
    October 01, 2007 - risk estimate of 1.93, which can be interpreted as a 93% increased risk of stroke (or an increase by a factor … , the latest systematic review has shown that HRT is associated with a 29% higher risk of stroke (a factor

  8. Technical Brief Disposition of Comments Report for Gene Expression Profiling for Predicting Outcomes in Stage II Colon Cancer (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/colon-cancer-gene-profiling_disposition-comments.pdf
    December 14, 2012 - ColoPrint is repeatedly the only factor that is significant in the multivariate analysis, indicating

  9. Multiple-Sclerosis Executive (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/multiple-sclerosis_executive.pdf
    April 01, 2015 - We concentrated on outcomes that patients notice or factor directly into their decisionmaking, such … Designs ranged from factor analysis of questionnaires to experimental psychology lab tests to trials … Cost was a factor in both self-report and through observation of purchasing behavior. … be a deterrent to patients with MS starting injectable DMTs, and “shot-fatigue” is a significant factor

  10. Appendix Table B-3. Observational Studies of Masks in Healthcare Settings (xls file)

    effectivehealthcare.ahrq.gov/sites/default/files/pdf/masks-appendix-table-b-3-version-1.xlsx
    February 01, 2020 - Appendix Table B-3. Observational Studies of Masks in Healthcare Settings B-3. Obs Studies Masks HCWs Archived: This living report is not being updated. Findings may be used for research purposes, but should not be considered current. Appendix Table B-3. Observational studies of masks in healthcare settings Author …

  11. App-E-Opioid-Chronic-Pain-Surveillance-Report-3 (xls file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-opioid-chronic-pain-surveillance-report-3.xlsx
    January 01, 2021 - Table E-1. RCT QA Table E-1. RCT quality assessment Author, Year Randomization Adequate? Allocation Concealment Adequate? Groups Similar at Baseline? Outcome Assessors Masked? Care Provider Masked? Patient Masked? Intention-To-Treat (ITT) Analysis Acceptable Levels of Overall Attrition and Between-Group Differences…

  12. McCormack-notes-151008 copy - Teresa (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/mccormack-presentation.pdf
    May 29, 2025 - talk today is about engaging patients with  low health  literacy. 1 Health literacy is a key factor

  13. Improving the Management of Menopausal Symptoms in Perimenopausal and Early Postmenopausal Women: A Systematic Review (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/menopausal-symptoms-protocol.pdf
    October 15, 2024 - or care or healthcare)).ti,bt,ab,kf. 147358 72 ((factor?

  14. #05 DEPRESSION (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1412.pdf
    December 01, 2014 - Specifically, ketamine-mediated increases in brain-derived neurotrophic factor (BDNF) levels are hypothesized … to activate mammalian target of rapamycin (mTOR) and inhibit eukaryotic elongation factor 2 kinase … Intervention: SPARX (Smart, Positive, Active, Realistic, X-factor) is a thoughts-depression– intervention … Untreated patient rates could also decline if SPARX diffuses; experts stated that this factor could … The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine.

  15. Skin Substitutes for Treating Chronic Wounds (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/pdf/skin-substitute_0.pdf
    October 03, 2019 - Skin Substitutes for Treating Chronic Wounds Evidence-based Practice Center Technical Brief Protocol Project Title: Skin Substitutes for Treating Chronic Wounds Initial publication date: November 27, 2018 Amendment Dates: July 24, 2019, October 3, 2019 (Amendments Details–see Section VII) I. Background an…

  16. Evidence Summary for CER 239: Acute Treatments for Episodic Migraine (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/cer-239-acute-migraine-evidence-summary.pdf
    December 01, 2020 - Additionally, the use of opioids for the acute treatment of migraine has been identified as a risk factor

  17. Treatments for Acute Pain: A Systematic Review (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/pdf/ehc-protocol-acute-pain-treatments.pdf
    August 08, 2019 - Treatments for Acute Pain: A Systematic Review Evidence-based Practice Center Systematic Review Protocol Project Title: Treatments for Acute Pain: A Systematic Review I. Background and Objectives for the Systematic Review Pain is nearly universal, contributing substantially to morbidity, mortality, disab…

  18. Psoriasis-Chronic Executive (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/psoriasis-chronic_executive.pdf
    November 01, 2012 - specific steps in the pathogenesis of psoriasis involving T cells and cytokines [e.g., tumor necrosis factor … Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis … serum creatinine SF-36 Short Form-36 Health Survey TCP thrombocytopenia TNF tumor necrosis factor

  19. S16 (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/s16.pdf
    October 01, 2007 - Surrogate outcomes such as change in a risk factor (eg, bone density) or disease marker (eg, tumor progression … with hypertension 8,883 (62.3) 4 3.7 19 0.7 1.4 89 1.2 PPP Men and women with �1 cardiovascular risk factor

  20. EHC Research Protocol: Documentation Burden (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/documentation-burden-protocol.pdf
    July 26, 2023 - are multiple contributors driving these issues, but documentation burden is commonly cited as a key factor
SHARE:
Facebook Twitter Print Facebook Share

Similar Terms:

Search the AHRQ Archive

Information and reports more than 5 years old may be found in the AHRQ Archive site.

Search Archive

Search Within A Specific AHRQ Site

You selected to view results for the following site:

View results from all sites